Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03945045
Other study ID # 201807144RINC
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 21, 2019
Est. completion date January 2024

Study information

Verified date August 2022
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare IJV and SCV as the implantation site of TIVAD and its associated thrombotic or occlusion rate, our study plans to enroll 240 patients with cancer who require central line TIVADs and randomizes them with 1:1 ratio to receive the TIVAD implantation at SCV or IJV. After the implantation, the patients will be regularly followed through phone contact and chart review for 2 years, and any symptomatic thrombosis or occlusion will be found during chemotherapy injection or regular push-pull heparin saline flush every 6 weeks as our hospital care protocol. To detect any asymptomatic thrombosis, the patients will also receive screening vascular ultrasound at 2 weeks, 2 months, and 6 months postoperatively. The study primary endpoints include any infection, asymptomatic thrombosis found by screen ultrasound, and clinically symptomatic thrombosis or occlusion and major mechanical failure/dislocation of TIVAD.


Description:

A totally implantable venous access device (TIVAD) provides reliable, long-term vascular access and improves cancer patients' quality of life. The use of TIVADs is associated with important complications as infection and venous thrombosis, and studies have shown that several factors are associated, such as cancer types, catheter types, and the location of the catheter tips. Whether subclavian vein(SCV)or internal jugular vein(IJV) is a better site for TIVAD percutaneous access were also widely studied, and there is no definite consensus generated yet. A meta-analysis published in 2016 by Wu et al reviewed 12 studies comparing the internal jugular vein (IJV) with the subclavian vein (SCV) as the percutaneous access site found no differences of TIVAD-related infection and catheter-related thrombotic rate. In the secondary outcome, IJV was associated with reduced risks of total major mechanical complications such as catheter dislocation and malfunction. Of 12 studies included, only 3 were randomized trial and there was no consistency between groups of using ultrasound guidance throughout TIVAD insertion. To be further, there is no description of how close to IJV-SCV junction does IJV group were inserted. Hence, a large well-designed RCT is warranted before the IJV site can be recommended. To compare IJV and SCV as the implantation site of TIVAD and its associated thrombotic or occlusion rate, our study plans to enroll 240 patients with cancer who require central line TIVADs and randomizes them with 1:1 ratio to receive the TIVAD implantation at SCV or IJV. After the implantation, the patients will be regularly followed through phone contact and chart review for 2 years, and any symptomatic thrombosis or occlusion will be found during chemotherapy injection or regular push-pull heparin saline flush every 6 weeks as our hospital care protocol. To detect any asymptomatic thrombosis, the patients will also receive screening vascular ultrasound at 2 weeks, 2 months, and 6 months postoperatively. The study primary endpoints include any infection, asymptomatic thrombosis found by screen ultrasound, and clinically symptomatic thrombosis or occlusion and major mechanical failure/dislocation of TIVAD.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 201
Est. completion date January 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 99 Years
Eligibility Inclusion: 240 cancer patients, 20~99 years old. Exclusion: 1. Breast cancer, mediastinal tumor above 6 cm, head and neck cancer with/without surgical/radiological treatment, lung tumor above 6 cm, 2. ECOG (Eastern Cooperative Oncology Group)performance status>=2, can't tolerate sit-upright or standing postoperative chest plain film, 3. Allergy to prophylactic antibiotic, 4. History of previous TIVAD or Hickman catheter implantation. Recent 2 weeks Central venous catheter insertion. 5. End stage renal disease.

Study Design


Intervention

Procedure:
Subclavian vein approach
Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
internal jugular vein approach
internal jugular vein approach for Ultrasound-guided Implantation of TIVAD

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary infection (blood stream or local wound) catheter-related blood stream infection(CRBSI) due to TIVAD, including:
1-1. at least one positive blood culture obtained from a peripheral vein, clinical manifestations of infections (i.e., fever, chills, and/or hypotension), and no apparent source for the blood stream infection, except the TIVAD, which leads to the TIVAD removal. Subsequent TIVAD catheter tip culture yields the same organism.
1-2. Differential time to positivity, with blood culture drawn from the TIVAD that becomes positive at least 2 hr earlier than the peripheral blood culture.
TIVAD local wound infection and/or non-healing will be classified as infection.
2 years
Primary asymptomatic venous thrombosis asymptomatic venous thrombosis found by study initiated screening ultrasound at 2 weeks, 2 months, and 6 months postoperatively.
asymptomatic venous thrombosis found by chart review of chest CT/plain film, if exams are available due to other medical indication within 2 years postoperatively.
2 years
Primary symptomatic venous thrombosis with positive confirmatory image tests both positive symptoms and positive confirmative image tests should be met.
Positive symptom noted by the patient or caregiver, such as
any arm swelling or swelling sensation
suspicious pulmonary embolism with symptom as dyspnea, chest tightness/pain, Hemoptysis...etc.
Positive confirmatory image tests as
vascular sonography
Catheter-based angiography
Computed tomographic pulmonary angiography (CTPA) or magnetic resonance pulmonary angiography (MRPA)
Ventilation perfusion (V/Q) scanning when pulmonary embolism is suspected.
2 years
Primary TIVAD catheter occlusion Failure or difficult to infuse fluid or withdraw blood from TIVAD. Difficult to withdraw blood from TIVAD in certain body position is not counted. 2 years
Primary major mechanical failure, dislocation of TIVAD. catheter kinking, looping, migration to different vessel
catheter disintegration from port.
2 years
Secondary Intolerable pain or foreign body sensation of TIVAD Subjectively, intolerable "pain or foreign body sensation" of TIVAD, which leads to TIVAD remove without other medical reasons.
Patient requests for TIVAD remove with no pain, no foreign body sensation, and no other medical reasons will not be included in the measure. (that is, "I want to remove TIVAD because TIVAD is an implant")
2 years
See also
  Status Clinical Trial Phase
Completed NCT02567903 - Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System N/A
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Recruiting NCT02650453 - Ongoing Registry of Deep Venous Reconstructions N/A
Completed NCT02065388 - Pharmacogenetic Dosing of Warfarin Phase 3
Completed NCT00839657 - Clarification of Optimal Anticoagulation Through Genetics Phase 3
Terminated NCT00872079 - Personalized Warfarin Dosing by Genomics and Computational Intelligence N/A
Terminated NCT00521885 - Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients N/A
Completed NCT02892565 - Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System) N/A
Completed NCT00346424 - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters Phase 3
Active, not recruiting NCT04349189 - Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Recruiting NCT02238444 - Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Phase 4
Recruiting NCT02597218 - Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Completed NCT00246025 - A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery. Phase 2
Completed NCT00097357 - BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery Phase 2/Phase 3
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT) Phase 4
Recruiting NCT02264743 - Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Phase 4
Completed NCT01482273 - Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis N/A
Recruiting NCT01252420 - Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Phase 4
Completed NCT01145859 - Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects Phase 1